Abiraterone acetate for prostate cancer: a new era of hormonal therapies.

about

Molecular characterization of a novel androgen receptor transgene responsive to MicroRNA mediated post-transcriptional control exerted via 3'-untranslated region.Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer.

P2860

Q38785291-AC0649A0-CE7E-4494-89D1-1F2787212C8B Q46253252-B07630B3-8096-4376-97EE-9ECF44354957

P2860

Abiraterone acetate for prostate cancer: a new era of hormonal therapies.

Item

http://www.wikidata.org/entity/Q41997785

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Abiraterone acetate for prostate cancer: a new era of hormonal therapies.

@en

type

Item

label

Abiraterone acetate for prostate cancer: a new era of hormonal therapies.

@en

prefLabel

Abiraterone acetate for prostate cancer: a new era of hormonal therapies.

@en

P1476

Abiraterone acetate for prostate cancer: a new era of hormonal therapies

@en

P2093

Emmanuel S Antonarakis

http://www.w3.org/2001/XMLSchema#string

P2860

New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Abiraterone and increased survival in metastatic prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer

Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Expanding treatment options for metastatic prostate cancer

Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.

P304

663-664

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/AJA.2011.92

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Emmanuel S Antonarakis

P577

2011-07-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51481020

http://www.w3.org/2001/XMLSchema#string

P698

21743483

http://www.w3.org/2001/XMLSchema#string

P921

abiraterone acetate

P932

3739597

http://www.w3.org/2001/XMLSchema#string

Abiraterone acetate for prostate cancer: a new era of hormonal therapies.

about

P2860

P2860

Abiraterone acetate for prostate cancer: a new era of hormonal therapies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932